News Wire ~ 3rd Party Press Release
Study Finds Biologic Drug Highly Effective in Reducing Pediatric Eczema Symptoms
Infants and young children finally get relief from eczema’s terrible itch
New Blood Test Accurately Determines the Threshold Dose for Reactions to Peanuts
Allergenis’ bead-based epitope assay is a breakthrough diagnostic for peanut allergy.
Siolta Begins Phase 2 Study in Newborns of Bacteria Consortia to Prevent Atopic...
STMC-103H has a combination of bacteria that are depleted in the gut microbiota of infants who go on to develop allergic sensitization and allergic diseases in childhood.
Enjoy Life Expands Voluntary Recall of Select Bakery Products Due to Potential Presence of Foreign...
See updated list of recalled products.
UnitedHealthcare: $0 Copay for Epinephrine, Albuterol, Insulin, Glucagon, Naloxone Starting Jan 1, 2023
Eligible members will pay $0 out of pocket for insulin and emergency use drugs that are critical in acute, life-saving circumstances.
Dupixent® Phase 3 Trial Shows Positive Results in Children Ages 1-11 with Eosinophilic Esophagitis...
Majority of patients achieved histological disease remission in 16 weeks.
Alpha-Gal Syndrome May Be Caused by the Body’s Defense Against Parasites Gone Haywire
Genetic and molecular insights into dangerous tick bite-related meat allergy revealed.
Enjoy Life Issues Nationwide Voluntary Recall of Select Bakery Products Due to Potential Presence of...
See list of recalled products.
American Academy of Pediatrics Updates Recommendations Regarding School Preparedness for Medical Emergencies
Be sure to share the recommendations with your child's school administration.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
